---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024046"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2024-06-17T23:59:59+00:00"
generated_at: "2026-06-01T04:03:44.561744+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MyMD appoints Glass as President/CMO, Friscia to board; Chapman departs; preferred shares increased

## Summary
- Mitchell Glass, M.D. appointed President & CMO effective June 13, 2024; no additional compensation.
- Stephen Friscia appointed to board of directors, nominated by PharmaCyte Biotech per SPA.
- Christopher Chapman, M.D. resigned as President, CMO and director effective June 14, 2024; separation includes $125K installments, $25K one-time, COBRA, option acceleration.
- Amendment filed to increase authorized Series G Preferred shares from 8,950 to 12,826,273 for in-kind dividends.
- Chapman's departure amicable; he will focus on Telomir Pharmaceuticals (TELO).

## SEC filing metadata
- accession: 0001493152-24-024046
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2024-06-17T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 3.03, 5.02, 5.03, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/0001493152-24-024046-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024046
- JSON: https://secwatch.observer/filing/0001493152-24-024046.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024046.txt

## Key facts
- Executive change
  Stephen Friscia was appointed as Director at Q/C TECHNOLOGIES, INC..
  - Action: appointed
  - Role: Director
  source text: On June 13, 2024, Mr. Stephen Friscia was appointed to serve as a member of the Board until his successor has been duly elected and qualified or until his earlier resignation or removal.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/0001493152-24-024046-index.htm
- Executive change
  Christopher Chapman resigned as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..
  - Action: resigned
  - Role: President and Chief Medical Officer
  source text: the Company and Christopher Chapman, M.D. mutually agreed on the separation of Dr. Chapman from his position as President, Chief Medical Officer and member of the board of directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/0001493152-24-024046-index.htm
- Executive change
  Mitchell Glass was appointed as President and Chief Medical Officer at Q/C TECHNOLOGIES, INC..
  - Action: appointed
  - Role: President and Chief Medical Officer
  source text: On June 13, 2024, the Company appointed Mitchell Glass, M.D., a current member of the Board, to the positions of President and Chief Medical Officer, effective as of June 13, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1321834/000149315224024046/0001493152-24-024046-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.